Abstract
The present work is an extension of our ongoing efforts towards the development and identification of new molecules with anti-HIV activity which have previously led to the discovery of arylazolylthioacetanilides as highly active NNRTIs. In this article, a series of 2-2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamide derivatives were synthesized and evaluated for in vitro anti-HIV activity. Most of the tested compounds exhibited moderate activities against wild-type HIV-1. Among them, compound 6k showed significant activity against wild-type HIV-1 with an EC50 value of 1.7μM, along with moderate activity against wild-type reverse transcriptase (RT). The preliminary structure–activity relationship (SAR) and docking calculations of this new series of compounds were also investigated, which may help designing more potent molecules.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have